Download the full-sized PDF of Development of stat-3 targeting siRNA nano-carriers for cancer therapyDownload the full-sized PDF



Permanent link (DOI):


Export to: EndNote  |  Zotero  |  Mendeley


This file is in the following communities:

Graduate Studies and Research, Faculty of


This file is in the following collections:

Theses and Dissertations

Development of stat-3 targeting siRNA nano-carriers for cancer therapy Open Access


Other title
Drug Delivery
Type of item
Degree grantor
University of Alberta
Author or creator
Alshamsan, Aws
Supervisor and department
Lavasanifar, Afsaneh (Faculty of Pharmacy and Pharmaceutical Sciences)
El-Kadi, Ayman (Faculty of Pharmacy and Pharmaceutical Sciences)
Examining committee member and department
Unsworth, Larry D. (Chemical and Materials Engineering)
Suresh, Mavanur R. (Faculty of Pharmacy and Pharmaceutical Sciences)
Uludağ, Hasan (Chemical and Materials Engineering)
Nazarali, Adil (Division of Pharmacy, University of Saskatchewan)
Faculty of Pharmacy and Pharmaceutical Sciences

Date accepted
Graduation date
Doctor of Philosophy
Degree level
In many tumors, persistently-active signal transducer and activator of transcription 3 (STAT3) imparts several oncogenic features such as survival, proliferation, angiogenesis, and immune escape. Therefore, STAT3 targeting in cancer and cancer-exposed dendritic cells (DCs) is important for cancer therapy. Our objective is developing delivery modalities of STAT3-targeting small interfering RNA (siRNA) using lipid-modified polyethylenimine (PEI) polyplexes and poly(D,L lactic-co-glycolic) acid (PLGA) nanoparticles (NPs), and evaluating the therapeutic outcomes in vitro and in vivo. Significant increase in siRNA condensation, protection, and cellular uptake by B16.F10 melanoma was seen by stearic-acid-modified PEI (PEI-StA) compared to unmodified PEI. Moreover, PEI-StA increased the STAT3 silencing potency of siRNA compared to PEI. STAT3 knockdown was accompanied with significant induction of interleukin-6 (IL-6) secretion and reduction of vascular endothelial growth factor (VEGF) production and cytotoxicity evidenced by increased Caspase 3 activity in vitro and in vivo, and significant inhibition in tumor growth. Analysis of tumor microenvironment showed CD3+ cells infiltration corresponding to STAT3 knockdown. The levels of CD4+ helper cells, CD8+ cytotoxic cells, and NKT cells significantly increased. DC infiltration and activation significantly increased in tumor mass following STAT3 knockdown as evidenced by high expression of CD86 and CD40. Moreover, IFN-, IL-12, and TNF- significantly increased following STAT3 knockdown by PEI-StA compared to PEI, suggesting Th1-type immunity. Allogenic capacity of DCs isolated from siRNA-treated mice was evidenced by the high T cell proliferation and IL-2 production in mixed lymphocytes reaction (MLR). Then, we explored STAT3 knockdown in DCs exposed to tumor derived factors (TDFs). We investigated encapsulation of siRNA complexes (PEI or PEI-StA) into PLGA NPs (PLGA-P and PLGA-PS). PLGA-P and PLGA-PS had an average diameter of ~ 370 nm and zeta potential of ~ -16 mV. Uptake and endosomal localization was confirmed. After TDFs exposure, DCs showed high STAT3 and low CD86 expression. STAT3 silencing by PLGA-P and PLGA-PS restored DC functionality as evidenced by upregulation of CD86, IL-12, and TNF- and MLR activity. PLGA significantly reduced PEI-associated toxicity. Therefore, STAT3 targeting in B16 cells by siRNA polyplexes of PEI and PEI-StA, or in DCs by PLGA-P and PLGA-PS provide potential strategies for cancer therapy.
License granted by Aws Alshamsan ( on 2010-07-08T02:31:33Z (GMT): Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of the above terms. The author reserves all other publication and other rights in association with the copyright in the thesis, and except as herein provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission.
Citation for previous publication

File Details

Date Uploaded
Date Modified
Audit Status
Audits have not yet been run on this file.
File format: pdf (Portable Document Format)
Mime type: application/pdf
File size: 3044874
Last modified: 2015:10:12 20:36:13-06:00
Filename: Alshamsan_Aws_Fall 2010.pdf
Original checksum: 7833d313797576557eeb3b4f8450ddff
Well formed: true
Valid: true
Status message: Too many fonts to report; some fonts omitted. Total fonts = 1047
File title: 0-titlewith
File title: University of Alberta
File author: Faculty of Graduate Studies and Research
Page count: 273
Activity of users you follow
User Activity Date